Addition of tipifarnib to existing MAPK inhibitor treatment regimens has shown promise in HRAS-driven thyroid cancer, further inhibiting ERK activation and abrogating HRAS mutant signalling (Untch et al., 2018). This evidence concerns the gene HRAS and thyroid gland carcinoma.